The pharmaceutical segment of Johnson & Johnson was the company’s strongest segment during 2018, generating over 40 billion U.S. dollars of revenue globally. The rise of pharmaceuticals as the company’s leading segment began in 2013, when it was about even with the medical devices and diagnostics segment for the first time. Johnson & Johnson’s third pillar is the consumer health segment.
Johnson & Johnson company overview
New Jersey-based Johnson & Johnson is a global diversified healthcare company, with the pharmaceutical business becoming increasingly dominant over time. Within Johnson & Johnson’s pharmaceutical segment, oncology and immunology are the major therapeutic areas. But Johnson & Johnson also has two other strong business segments: medical devices and diagnostics, and consumer packaged goods. In fact, these segments rank J&J among the world’s top 10 medical technology companies as well as the world’s number one consumer health company.
The company’s pharmaceutical segment
Since 2013, the pharmaceutical segment showed significant growth within J&J’s segments. That the company shows particular engagement in this field is also visible by the size of its R&D pipeline which is one of the largest within the pharma industry, as of 2019. Only Novartis and Takeda showed a higher count of drugs in the pipeline. Johnson & Johnson was also ranked second worldwide based on the number of originated drugs, as of the same year. These developments are comprehensible when taking into account the company’s share of revenue which is invested into research and development. Since 2010, it has shown an almost constant increase.
Johnson & Johnson company overview
New Jersey-based Johnson & Johnson is a global diversified healthcare company, with the pharmaceutical business becoming increasingly dominant over time. Within Johnson & Johnson’s pharmaceutical segment, oncology and immunology are the major therapeutic areas. But Johnson & Johnson also has two other strong business segments: medical devices and diagnostics, and consumer packaged goods. In fact, these segments rank J&J among the world’s top 10 medical technology companies as well as the world’s number one consumer health company.
The company’s pharmaceutical segment
Since 2013, the pharmaceutical segment showed significant growth within J&J’s segments. That the company shows particular engagement in this field is also visible by the size of its R&D pipeline which is one of the largest within the pharma industry, as of 2019. Only Novartis and Takeda showed a higher count of drugs in the pipeline. Johnson & Johnson was also ranked second worldwide based on the number of originated drugs, as of the same year. These developments are comprehensible when taking into account the company’s share of revenue which is invested into research and development. Since 2010, it has shown an almost constant increase.
